Targeted treatment of T-cell acute lymphoblastic leukemia: latest updates from the 2022 ASH Annual Meeting

Overview of attention for article published in Experimental Hematology & Oncology, March 2023

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (57th percentile)
Above-average Attention Score compared to outputs of the same age and source (61st percentile)

So far, Altmetric has seen 6 X posts from 6 X users, with an upper bound of 18,485 followers.

Targeted treatment of T-cell acute lymphoblastic leukemia: latest updates from the 2022 ASH Annual Meeting https://t.co/NrdkGqYyZj

RT @Anand_88_Patel: A succinct summary of therapies in T-cell ALL that were featured at the @ASH_hematology #ASH22 annual meeting! #leusm…

RT @Anand_88_Patel: A succinct summary of therapies in T-cell ALL that were featured at the @ASH_hematology #ASH22 annual meeting! #leusm…

RT @Anand_88_Patel: A succinct summary of therapies in T-cell ALL that were featured at the @ASH_hematology #ASH22 annual meeting! #leusm…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 2 additional X posts.